Nina Totenberg

Moderator
Nina Totenberg
Legal Affairs Correspondent, National Public Radio, Washington, DC

Panelists
Philip A. Pizzo, MD
Dean and Professor of Pediatrics and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA

Thomas P. Stossel, MD
Professor of Medicine, Harvard Medical School, Boston, MA

P. Roy Vagelos, MD
Chairman, Regeneron Pharmaceuticals, Inc.; Chairman, Theravance, Inc.; Former CEO, Merck & Co., Inc.

Dr. Stossel reported that he has ownership interests in ZymeQuest, Inc., and in Critical Biologics Corp.; has intellectual property rights in Critical Biologics Corp.; has received consulting/advisory fees from Merck, Inc.; has received honoraria from Pfizer, Inc.; and has received royalties from Lippincott Williams & Wilkins.

All other participants reported that they have no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.

Moderator
Nina Totenberg
Legal Affairs Correspondent, National Public Radio, Washington, DC

Panelists
Philip A. Pizzo, MD
Dean and Professor of Pediatrics and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA

Thomas P. Stossel, MD
Professor of Medicine, Harvard Medical School, Boston, MA

P. Roy Vagelos, MD
Chairman, Regeneron Pharmaceuticals, Inc.; Chairman, Theravance, Inc.; Former CEO, Merck & Co., Inc.

Dr. Stossel reported that he has ownership interests in ZymeQuest, Inc., and in Critical Biologics Corp.; has intellectual property rights in Critical Biologics Corp.; has received consulting/advisory fees from Merck, Inc.; has received honoraria from Pfizer, Inc.; and has received royalties from Lippincott Williams & Wilkins.

All other participants reported that they have no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.

Moderator
Nina Totenberg
Legal Affairs Correspondent, National Public Radio, Washington, DC

Panelists
Philip A. Pizzo, MD
Dean and Professor of Pediatrics and of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA

Thomas P. Stossel, MD
Professor of Medicine, Harvard Medical School, Boston, MA

P. Roy Vagelos, MD
Chairman, Regeneron Pharmaceuticals, Inc.; Chairman, Theravance, Inc.; Former CEO, Merck & Co., Inc.

Dr. Stossel reported that he has ownership interests in ZymeQuest, Inc., and in Critical Biologics Corp.; has intellectual property rights in Critical Biologics Corp.; has received consulting/advisory fees from Merck, Inc.; has received honoraria from Pfizer, Inc.; and has received royalties from Lippincott Williams & Wilkins.

All other participants reported that they have no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.

Moderator
Nina Totenberg
Legal Affairs Correspondent, National Public Radio, Washington, DC

Panelists
Darrell G. Kirch, MD
President and CEO, Association of American Medical Colleges, Washington, DC

Paul A. LaViolette, MBA
Chief Operating Officer, Boston Scientific Corporation, Natick, MA; Member, Board of Directors, and Chairman, Special Committee on Codes of Ethics, AdvaMed

Norka Ruiz Bravo, PhD
Deputy Director for Extramural Research, National Institutes of Health, Bethesda, MD

Mr. LaViolette reported that he has no financial interests or relationships that pose a potential conflict of interest with this article apart from his employment with Boston Scientific Corp., from which he receives a salary and in which he holds ownership interest.

All other participants reported that they have no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.

Moderator
Nina Totenberg
Legal Affairs Correspondent, National Public Radio, Washington, DC

Panelists
Darrell G. Kirch, MD
President and CEO, Association of American Medical Colleges, Washington, DC

Paul A. LaViolette, MBA
Chief Operating Officer, Boston Scientific Corporation, Natick, MA; Member, Board of Directors, and Chairman, Special Committee on Codes of Ethics, AdvaMed

Norka Ruiz Bravo, PhD
Deputy Director for Extramural Research, National Institutes of Health, Bethesda, MD

Mr. LaViolette reported that he has no financial interests or relationships that pose a potential conflict of interest with this article apart from his employment with Boston Scientific Corp., from which he receives a salary and in which he holds ownership interest.

All other participants reported that they have no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.

Moderator
Nina Totenberg
Legal Affairs Correspondent, National Public Radio, Washington, DC

Panelists
Darrell G. Kirch, MD
President and CEO, Association of American Medical Colleges, Washington, DC

Paul A. LaViolette, MBA
Chief Operating Officer, Boston Scientific Corporation, Natick, MA; Member, Board of Directors, and Chairman, Special Committee on Codes of Ethics, AdvaMed

Norka Ruiz Bravo, PhD
Deputy Director for Extramural Research, National Institutes of Health, Bethesda, MD

Mr. LaViolette reported that he has no financial interests or relationships that pose a potential conflict of interest with this article apart from his employment with Boston Scientific Corp., from which he receives a salary and in which he holds ownership interest.

All other participants reported that they have no financial interests, relationships, or affiliations that pose a potential conflict of interest with this article.